Functional Dyspepsia
Article information
J Korean Med Assoc. 2005;48(1):48-58
Publication date (electronic) : 2005 February 17
doi :
https://doi.org/10.5124/jkma.2005.48.1.48
Abstract
Functional dyspepsia (FD) is a complex disease reaction that occurs due to the presence of various factors, and its pathophysiology has not been clearly understood yet. FD is a diagnosis of exclusion after ruling out organic diseases. Therefore, the main treatments are limited to relieving symptoms through supportive care. The international prevalence of FD based on the Rome I criteria is approximately 25%. In Korea, there are very omnifarious symptoms in gastrointestinal disorders, and the medical vocabularies that describe the diagnostic standard are not closely associated with the daily vocabularies., Thus there would be a lot of restrictions in direct application of the Rome II criteria. However, the Korean Society of Gastrointestinal Motility had decided to promote the use of the international standardized Rome II criteria to be comparable to the clinical studies from other nations. There should be more extensive studies to differentiate the definitions of symptoms in Korea from those in other countries. The extended researches concerning the pathophysiology of FD are needed to find reliable treatment modalities for the disease.
Keywords: Functional dyspepsia; Rome II criterior; Visceral hypersensitivity; Helicobacter pylori; Prokinetic agents
References
4. Choi H, Choi MG, Kim SW, Moon SB, Kim BK, SUN HS, et al. Functional gastrointestinal disorders in patients with gastrointestinal symptoms. Korean J Gastroenterol 1999. 33741–748.
5. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999. 45suppl 2. II1–II5.
7. Mayer EA, Gebbart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994. 107271–293.
8. Manakata J, Naliboff B, Harraf E, Konder A, Lembo T, Mayer EA, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997. 11255–63.
9. Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol Suppl 1992. 192102–105.
10. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Read NW, et al. The role of Psychological and biological fuctors in post-infective gut dysfunction. Gut 1999. 44400–406.
11. Mayer EA, Raybould HE. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 1990. 991688–1704.
12. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared to subjects without bowel dysfuction. Gut 1992. 33825–830.
13. Talley NJ, Axon A, Bytzer P, Holtmann A, Lam A, S Velouhuyzen van Zanten. Management of uninvestigated and functional dyspepsia: a working party report for the World Congress of Gastroenterology 1998. Aliment Pharmacol Ther 1999. 131135–1148.
14. Adang RP, Vismans JF, Talmon JL, Hasman A, Ambergen AW, Stockbrügger RW. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc 1995. 42390–397.
15. Horrocks JC, De Dombal FT. Clinical presentation of patients with 'dyspepsia'. Detailed symptomatic study of 360 patients. Gut 1978. 1919–26.
16. McColl K, Murray L, EL-Omar E, Dickson A, EL-Nujumi A, Hilditch T, et al. Symptomatic benefit from eradicating Helicobater pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998. 3391869–1874.
17. Blum AL, Talley NJ, O'Morian C, Van Zanten SV, Labenz J, Junghard O, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998. 3391875–1881.
18. Talley NJ, Jassens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomized double blind placebo controlled trial with 12 months' follow up. BMJ 1999. 318833–837.
19. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradication Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999. 3411106–1111.
20. Greydanus MP, Vassallo M, Camilleri M, Nelson DK, Hanson RB, Thomforde GM. Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms. Gastroenterology 1991. 1001311–1318.
21. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994. 27265–69.
22. Joshua JO, Jeff E, Steven F, Katherine LK, Andrew HS. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences. Annals of Internal Medicine 1997. 126280–291.
23. Delaney DC. Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of dyspepsia. Br J Gen Pract 1995. 45489.
24. Sander JO, Veldhuyzen VZ, Cynthia C. Drug treatment of functional dyspepsia: a systemic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996. 91660.
25. Delattre M, Malesloy M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res 1985. 37980.
26. Berstad A, Wilhelmsen I. Gastric accommodation in functional dyspepsia. Scand J Gastroenterol 1997. 32193–197.
27. Talley NJ. Functional dyspepsia-should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995. 9107–115.
28. Heyse PM, Rambaldo R, Hazelhoff B. Factors affecting short- and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. Scand J Gastroenterol Suppl 1993. 19515–23.
29. Drossman DA, Corraziari E, Talley NJ. The functional gastrointestinal disorders 2000. 2nd edsth ed. McLean: Degnon Associates;
30. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990. 100497–501.
31. Wilmer A, Tack J, Coremans G. Effect of ondansetron, a 5-HT3 antagonist on perception of gastric distension and gastric compliance in healthy man(abstr). Gastroenterology 1993. 104A603.
32. Stark M Jr, Maher K, Gupta P. Visceral afferent blockade with ondansetron with noncardiac chest pain(abstr). Am J Gastroenterol 1991. 861305.
33. Talley NJ. 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992. 6273–289.
34. Resd NW, Bardhan KD, Whorwell PJ. Fedotozine in functional dyspepsia: results of a 6-week placebo-controlled multicenter therapeutic trial(abstr). Gastroenterology 1995. 108A676.
35. Li Y, Han JS. Cholegystokinin octapeptide antagonizes morphine analgesia in periaqueductal gray of the rat. Brain Res 1989. 480105–110.
36. Boulant J, Fioramounti J, Dapoiguy M, Bommelear G, Bueno L. Cholegystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distension in dogs. Gastroenterology 1994. 1071059–1066.
37. Bradette M, Delvaux M, Stsumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994. 391171–1178.
Article information Continued
Copyright © 2005 Korean Medical Association
